Hangzhou Biotest Biotech Co Ltd
SSE:688767
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
H
|
Hangzhou Biotest Biotech Co Ltd
SSE:688767
|
5.5B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.8B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Hangzhou Biotest Biotech Co Ltd
Glance View
Hangzhou Biotest Biotech Co., Ltd. engages in the research and development, production and sales of point-of-care testing (POCT) diagnostic reagents. The company is headquartered in Hangzhou, Zhejiang and currently employs 622 full-time employees. The company went IPO on 2021-09-08. The firm's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Hangzhou Biotest Biotech Co Ltd is 13.1%, which is above its 3-year median of 12.1%.
Over the last 3 years, Hangzhou Biotest Biotech Co Ltd’s Operating Margin has decreased from 48.6% to 13.1%. During this period, it reached a low of -22.1% on Sep 30, 2023 and a high of 48.6% on Aug 30, 2022.